Chiesi Farmaceutici S.p.a.

This study tests a drug called PRX-102 (pegunigalsidase alfa) in 22 children and teens aged 2 to 18 with Fabry disease, a rare genetic disorder that causes pain and organ damage. The drug is an enzyme replacement therapy given by infusion every two weeks. Researchers will monitor…

This study tests whether a triple-combination inhaler (containing an anti-inflammatory, a long-acting bronchodilator, and another bronchodilator) works better than a standard double-combination inhaler for people whose asthma is not well controlled. About 644 adults with asthma w…

This registry monitors the safety and effectiveness of metreleptin in up to 100 people with generalized or partial lipodystrophy who are already taking the drug in routine care. Researchers will track serious events like pancreatitis, liver problems, infections, and cancers. The …

This study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an …

This study looks at the long-term safety and effectiveness of a daily injection called metreleptin for people with familial partial lipodystrophy, a rare condition where fat is distributed abnormally. About 24 participants who completed a previous study will receive the drug for …

This study tests whether a new inhaler with three medicines (CHF 5993) works better than a standard two-medicine inhaler (CHF 1535) for people whose asthma is not well controlled. About 554 adults in China will use one of the two inhalers for 24 weeks. The main goal is to see if …

This study compares a new version of an asthma inhaler that uses a climate-friendly propellant to the current version. About 780 adults with mild to moderate asthma will try both inhalers to see if they work equally well. The goal is to ensure the greener option is just as effect…

This study is testing a drug called pegunigalsidase alfa in about 16 Japanese patients aged 13 to 70 with Fabry disease, a rare genetic disorder. The goal is to see if the drug is safe and how it works in the body. Participants will receive the treatment and be monitored for side…

This study tests a gel called Oleogel-S10 on skin wounds in people with inherited epidermolysis bullosa (EB), a condition that causes fragile, blistering skin. The trial includes 6 Japanese children and adults with junctional or dystrophic EB. Participants apply the gel to wounds…

This study follows about 100 adults with Fabry disease who are taking or planning to take the medication Elfabrio. Researchers will monitor kidney function, heart health, and disease markers over time to see how well the drug works and if any side effects occur. The goal is to un…

This early-stage trial tests the safety of an inhaled study drug called CHF6333. It involves 45 participants: first, healthy volunteers and people with bronchiectasis receive a single dose; then, people with bronchiectasis receive repeated doses. The goal is to check for side eff…

This 10-year observational registry will follow up to 10 women with Fabry disease who received pegunigalsidase alfa (Elfabrio) around the time of pregnancy or while breastfeeding, along with their infants. Researchers will track pregnancy outcomes, birth defects, and infant healt…

This early-stage trial is testing a new drug called CHF6467, given as a nasal spray, in 68 healthy adults. The main goal is to check if it is safe and how the body processes it, including how it moves into the blood and spinal fluid. The study will give either single or repeated …